Dr. Glenn Begley, CEO of BioCurate and a respected hematologist and oncologist, is famous for producing a study in 2012 that demonstrated most preclinical research related to cancer drugs cannot be reproduced. In this lecture, he shares the criteria he used for evaluating the research and the methods he found researchers used to distort their data. He then presents his diagnosis of the problem inherent in the academic research cycle, which he claims fuels the desperation that produces such distortions.

In this October 2018 editorial, Michael Hengartner and Martin Plöderl argue trials investigating the impact of antidepressants show statistically significant but not clinically significant effects, and even these meager effects may be eroded by known biases.